H
Hans Carl Hasselbalch
Researcher at University of Copenhagen
Publications - 347
Citations - 11015
Hans Carl Hasselbalch is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Myelofibrosis & Polycythemia vera. The author has an hindex of 47, co-authored 321 publications receiving 9329 citations. Previous affiliations of Hans Carl Hasselbalch include Herlev Hospital & University of Southern Denmark.
Papers
More filters
Journal ArticleDOI
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui,Giovanni Barosi,Gunnar Birgegård,Francisco Cervantes,Guido Finazzi,Martin Griesshammer,Claire N. Harrison,Hans Carl Hasselbalch,Rüdiger Hehlmann,Ronald Hoffman,Jean-Jacques Kiladjian,Kröger N,Ruben A. Mesa,Mary Frances McMullin,Animesh Pardanani,Francesco Passamonti,Alessandro M. Vannucchi,Andreas Reiter,Richard T. Silver,Srdan Verstovsek,Ayalew Tefferi +20 more
TL;DR: A review of critical concepts and recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues are presented.
Journal ArticleDOI
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Jacob Grinfeld,Jyoti Nangalia,E. Joanna Baxter,David C. Wedge,Nicos Angelopoulos,Robert Cantrill,Anna L. Godfrey,Elli Papaemmanuil,Gunes Gundem,Cathy MacLean,Julia Cook,Laura O'Neil,Sarah O’Meara,Jon W. Teague,Adam P. Butler,Charles E. Massie,Nicholas Williams,Francesca L. Nice,Christen Lykkegaard Andersen,Hans Carl Hasselbalch,Paola Guglielmelli,Mary Frances McMullin,Alessandro M. Vannucchi,Claire N. Harrison,Moritz Gerstung,Anthony R. Green,Peter J. Campbell +26 more
TL;DR: Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms and may support the treatment of patients with myelofibrosis.
Journal ArticleDOI
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Philip A. Beer,Peter J. Campbell,Linda M. Scott,Anthony J. Bench,Wendy N. Erber,David Bareford,Bridget S. Wilkins,John T. Reilly,Hans Carl Hasselbalch,Richard Bowman,Keith Wheatley,Georgina Buck,Claire N. Harrison,Anthony R. Green +13 more
TL;DR: It is demonstrated that MPL mutations outside exon 10 are uncommon in platelet cDNA and 4 different exon10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF are identified.
Journal ArticleDOI
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet
Tiziano Barbui,Ayalew Tefferi,Alessandro M. Vannucchi,Francesco Passamonti,Richard T. Silver,Ronald Hoffman,Srdan Verstovsek,Ruben A. Mesa,Jean-Jacques Kiladjian,Rèdiger Hehlmann,Andreas Reiter,Francisco Cervantes,Claire N. Harrison,Mary F. Mc Mullin,Hans Carl Hasselbalch,Steffen Koschmieder,Monia Marchetti,Andrea Bacigalupo,Guido Finazzi,Nicolaus Kroeger,Martin Griesshammer,Gunnar Birgegård,Giovanni Barosi +22 more
TL;DR: This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs), and both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.
Journal ArticleDOI
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
TL;DR: A link between chronic inflammation, atherosclerosis, and second cancer in MPNs favors early intervention at the time of diagnosis (statins and interferon-α2), the aims being to dampen chronic inflammation and clonal evolution and thereby also diminish concurrent disease-mediated Chronic inflammation and its consequences.